Evidence map›Paper›PMID 41657704›Full record

ReviewO&G open2026

Cesarean Scar Implantation in the Evolution of Placenta Accreta Spectrum: Implications for Recognition and Clinical Management.

Ilan E Timor-Tritsch, Karin A Fox, Yalda Afshar

Abstract readReview
In one paragraph

Review in O&G open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. In Reply.O&G open · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ilan E Timor-TritschDepartment of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas; Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Molecular Biology Institute, UCLA, Los Angeles, California.
Karin A FoxDepartment of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas; Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Molecular Biology Institute, UCLA, Los Angeles, California.
Yalda AfsharDepartment of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas; Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Molecular Biology Institute, UCLA, Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that cesarean scar implantation represents the earliest manifestation of placenta accreta spectrum (PAS) disorders, reflecting a continuous pathophysiologic process rather than distinct clinical entities. This article examines data supporting cesarean scar pregnancy as a precursor to a substantial proportion of PAS, particularly after cesarean delivery, and advocates for unified clinical approaches to these conditions. The global rise in cesarean deliveries has triggered parallel increases in PAS disorders, characterized by abnormal placental attachment at sites of myometrial scarring where regulatory decidual mechanisms are absent. Histopathologic studies demonstrate that cesarean scar implantation and PAS are often indistinguishable, likely representing different developmental stages of the same condition, with up to 70% of expectantly managed cesarean scar pregnancies progressing to PAS at delivery. First-trimester ultrasound enables early identification of high-risk pregnancies through the use of several cesarean scar pregnancy classification systems, including the crossover sign, which categorizes cesarean scar pregnancies based on the position of the gestational sac relative to the endometrial line. Additional classifications distinguish between "on-the-scar" and "in-the-niche" implantation and implantation position relative to the uterine midline in the transverse plane. These parameters predict PAS severity and outcomes. Despite compelling evidence connecting cesarean scar pregnancy and PAS, most literature focuses on them as separate entities, resulting in fragmented clinical approaches. Here, we propose framing the cesarean scar pregnancy as an early manifestation of PAS. Equipped with an appreciation of the natural history of PAS, we recommend targeted screening for women with prior cesarean delivery, uterine surgery, previous cesarean scar pregnancy, or suspected early pregnancy loss, with critical screening windows at 5-7 and 11-14 weeks of gestation. Early identification and risk stratification enable individualized management decisions through shared decision making to reduce maternal morbidity from unanticipated uterine rupture, hemorrhage, and fertility loss. Recognizing cesarean scar pregnancy as the earliest detectable manifestation of PAS transforms management from reactive to proactive risk mitigation and fertility-sparing approaches, potentially improving outcomes and reducing PAS-associated health care burdens worldwide.

Identifiers

PMID41657704
PMCPMC12879953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.